Company intelligence / Profile preview

Embrella Cardiovascular

Wayne, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Embrella Cardiovascular was a medical device company founded in 2007 that developed the Embrella Embolic Deflector System, a single-use, disposable device designed to protect the brain from emboli during transcatheter heart valve replacement and other coronary procedures. The device received CE Mark approval in Europe in May 2010 and completed its first clinical case in Canada. The company raised approximately $9 million across two funding rounds before being acquired by Edwards Lifesciences on March 11, 2011, for $43 million.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Consumable Medical Devices

Beyond the preview

Go deeper on Embrella Cardiovascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Embrella Cardiovascular.

Explore the full profile